CLINICAL TRIALS PROFILE FOR FEMARA

505(b)(2) Clinical Trials for FEMARA

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT02520063 ↗	Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer	Active, not recruiting	Novartis Pharmaceuticals	Phase 1/Phase 2	2016-02-01	This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.
New Combination	NCT02520063 ↗	Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer	Active, not recruiting	Tracon Pharmaceuticals Inc.	Phase 1/Phase 2	2016-02-01	This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.
New Combination	NCT02520063 ↗	Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer	Active, not recruiting	University of Alabama at Birmingham	Phase 1/Phase 2	2016-02-01	This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.

All Clinical Trials for FEMARA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	Cancer and Leukemia Group B	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	Eastern Cooperative Oncology Group	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	International Breast Cancer Study Group	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
NCT00003140 ↗	Letrozole After Tamoxifen in Treating Women With Breast Cancer	Completed	North Central Cancer Treatment Group	Phase 3	1998-08-24	RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.

Clinical Trial Conditions for FEMARA

Condition Name

Condition Name for FEMARA
Intervention	Trials
Breast Cancer	62
Metastatic Breast Cancer	11
Polycystic Ovary Syndrome	10
Breast Neoplasms	10

Condition MeSH

Condition MeSH for FEMARA
Intervention	Trials
Breast Neoplasms	119
Carcinoma	20
Polycystic Ovary Syndrome	14
Infertility	12

Clinical Trial Locations for FEMARA

Trials by Country

Trials by Country for FEMARA
Location	Trials
United States	678
Canada	43
Spain	22
Egypt	19
Ireland	14

Trials by US State

Trials by US State for FEMARA
Location	Trials
Texas	37
California	31
Florida	27
Massachusetts	25
Washington	23

Clinical Trial Progress for FEMARA

Clinical Trial Phase

Clinical Trial Phase for FEMARA
Clinical Trial Phase	Trials
PHASE3	2
PHASE1	1
Phase 4	23

Clinical Trial Status

Clinical Trial Status for FEMARA
Clinical Trial Phase	Trials
Completed	79
Recruiting	37
Active, not recruiting	26

Clinical Trial Sponsors for FEMARA

Sponsor Name

Sponsor Name for FEMARA
Sponsor	Trials
National Cancer Institute (NCI)	39
Novartis Pharmaceuticals	16
Novartis	15

Sponsor Type

Sponsor Type for FEMARA
Sponsor	Trials
Other	265
Industry	94
NIH	45

Femara (letrozole) Clinical Trials Update, Market Analysis, and Patent-Driven Launch/Revenue Projections

Last updated: May 20, 2026

Femara (letrozole) is an established endocrine therapy for postmenopausal estrogen receptor-positive (ER+) breast cancer. The clinical development landscape is dominated by lifecycle studies (adjuvant/extended therapy optimization, combinations, and sequencing) rather than new “blockbuster” indications, while market access is primarily driven by generic competition and payer choices. From a patent and exclusivity perspective, Femara’s core product exclusivity has long expired, so near-term market projection hinges on generic penetration, uptake of alternative aromatase inhibitors (AIs), and guideline adherence to low-cost regimens.

---

What is the latest clinical trial status for Femara (letrozole)?

Which Femara studies are still active (by focus: adjuvant, extended, sequencing)?

Femara trials have historically centered on:

• Adjuvant therapy (early-stage ER+ disease after surgery)
• Extended adjuvant therapy (switching or continuing after 4-5 years of initial endocrine treatment)
• Sequencing strategies (letrozole vs other endocrine agents in defined lines)
• Combination strategies (AI + targeted therapy where biologic rationale exists)

Featured snippet answer: Femara’s current “trial activity” profile is dominated by long-running or small-to-mid size lifecycle studies rather than first-in-class indication expansions, and it is largely supportive of dosing duration, sequencing, and regimen optimization.

How do new trial results typically affect practice for ER+ postmenopausal breast cancer?

When new results emerge, they usually translate into:

• Preferred selection of AI-based endocrine therapy in guideline-driven care pathways
• More granular duration guidance for extended adjuvant therapy
• Subgroup refinement (higher-risk patients, prior tamoxifen exposure, molecular risk markers)

---

What patents protect Femara (letrozole) and how strong is the patent estate?

What is the core intellectual property situation for Femara?

Femara is a legacy small molecule with broad generic availability. Patent estates for letrozole have largely cleared, with product-level exclusivity long expired. The remaining IP value, where it exists, is typically tied to:

• Specific formulation/process improvements
• Line-of-therapy or regimen patents (less common for broadly used small molecules)
• Brand-specific data exclusivity that does not block generic entry for unchanged active ingredient/route

Featured snippet answer: Femara’s brand-level patent protection has largely expired; the market is functionally an “off-patent” small-molecule AI segment.

What is the Orange Book status of Femara?

Femara’s entry is generally present with historic reference/updates, but practical access barriers are low because letrozole is off patent and widely substituted by generics.

---

When does Femara (letrozole) lose exclusivity and what generic entry risks exist?

Exclusivity timeline

• Drug exclusivity for the brand product: expired long ago.
• Practical barrier today: generic manufacturing and FDA ANDA approvals, plus payer formulary and substitution rules.

Featured snippet answer: There is no meaningful “remaining exclusivity clock” for Femara that would delay generic substitution in the US; any remaining constraints are unrelated to brand exclusivity and are mostly commercial.

What generic launch scenarios matter for Femara revenue projection?

Given high market maturity:

• Scenario A (base): incremental share loss to lower-priced generics and co-packers; brand captures minimal premium.
• Scenario B (downside): aggressive contracting drives further price compression, accelerating share erosion.
• Scenario C (upside): payer preference for specific generic labels or supply stability reduces churn; brand holds a small share via contracts.

---

How does Femara compare with other aromatase inhibitors for breast cancer market share?

Key comparators in postmenopausal ER+ AI therapy

• Anastrozole (lower dose cost and broad substitution)
• Exemestane (steroidal AI, mixed guideline role by region/setting)
• Letrozole (often favored for certain sequencing/extended therapy practices)

What drives AI selection in commercial practice?

• Lowest net cost under payer contracting
• Formulary placement and automatic substitution
• Toxicity tolerance and patient history (bone health management, arthralgia profiles)
• Persistence and adherence (fixed daily dosing; switching patterns post adverse events)

Featured snippet answer: Letrozole’s commercial position depends on relative net price and contracting rather than on meaningful clinical differentiation versus other AIs in most lines of therapy.

---

How many patents cover Femara formulations and manufacturing methods?

Formulation and process “evergreening”

For legacy small molecules, formulation IP tends to be narrower and often does not block ANDA entry for standard oral tablets/capsules. Where formulation/process patents exist, they typically cover:

• Particle size distribution/solid-state
• Tableting processes and excipient systems
• Stability enhancements

Featured snippet answer: Most “tablet-level” competitive barriers for letrozole today are commercial, not IP.

---

What patent litigation affects Femara (letrozole) generics?

Litigation as a near-term market driver

For mature drugs with long-expired exclusivity, litigation is rarely the bottleneck today. When it occurs, it usually relates to:

• Residual formulation/process patents
• Small manufacturing and method-of-use theories
• Settlement terms for specific ANDA defendants

Featured snippet answer: Femara’s current revenue exposure is more sensitive to contracting and generic price erosion than to incremental litigation risk.

---

What regulatory status does Femara have with FDA, including pathways for generics/biosimilars?

Is Femara under a biologic pathway?

No. Femara is a small molecule and is covered by standard ANDA frameworks for generics and NDA for the brand.

What does FDA review mean for competitive access?

FDA ANDA approval allows interchangeable substitution subject to:

• Bioequivalence requirements
• Labeling sameness to the reference listed drug
• Timely supply and distribution

Featured snippet answer: Regulatory gating for Femara is stable and mature; competitive access is driven by ANDA readiness and commercial contracting.

---

Market analysis for Femara (letrozole): demand, pricing, and competitive landscape

Demand drivers

• ER+ breast cancer incidence in postmenopausal patients
• Guideline adoption of AI therapy in early and extended adjuvant settings
• Persistence and adherence to long-course endocrine therapy

Pricing drivers

• Generic competition drives down list and net prices
• Payer pharmacy benefit manager (PBM) contracting compresses reimbursement
• Wholesale acquisition cost (WAC) declines and rebate dynamics determine net price

Competitive landscape

Femara competes primarily with:

• Generic letrozole products
• Alternative AIs (anastrozole, exemestane)

Featured snippet answer: Femara’s market is structurally price-compressed, with share and revenue determined more by net contracting outcomes than by differentiation.

---

Revenue projection for Femara (letrozole): base, downside, and upside paths

What can be projected given maturity (high level)

For an off-patent legacy small molecule:

• Revenue usually trends with patient demand growth offset by price erosion
• Brand revenue typically declines as generics gain or as formularies prefer lowest net price

Projection framework

Because Femara is mature, projection should be modeled as:

1. Unit demand: tied to ER+ postmenopausal incidence and endocrine therapy utilization
2. Net price: tied to generics’ competitive pricing and PBM contracting
3. Share: brand vs generics and switching among AIs

Featured snippet answer: The most likely direction is modest unit stability or growth with ongoing net-price compression, resulting in flat-to-declining brand revenue.

---

Does Femara have significant upcoming clinical or commercial catalysts?

Clinical catalysts

• Lifecycle optimization studies can influence duration/sequencing recommendations
• Biomarker stratification and combination exploration can shift subpopulation uptake

Commercial catalysts

• PBM formulary changes that select specific generic labels
• Local shortages/supply interruptions can temporarily increase prices for certain SKUs

Featured snippet answer: There is no single high-probability, near-term catalyst expected to materially reverse structural price pressure from generic competition.

---

Key Takeaways

• Femara (letrozole) is an off-patent, mature AI with ongoing clinical research focused on regimen optimization rather than new breakthrough indications.
• Patent and exclusivity barriers are not a meaningful near-term determinant of access; ANDA-based generic supply and payer contracting dominate competition.
• Revenue trajectory is primarily a function of net price compression and formulary dynamics, partially offset by demand for ER+ endocrine therapy.
• Near-term risks and upside are mostly commercial (pricing, contracting, supply), not regulatory or exclusivity-driven.

---

FAQs

1) Will Femara’s market share shift due to new AI competitors?

Share moves mainly with payer contracting and relative net price; clinical differentiation between AIs is usually secondary in mature settings.

2) How do extended adjuvant duration studies affect letrozole uptake?

They can influence how long patients stay on AI therapy, changing total treated-patient months even if per-patient drug choice stays similar.

3) What are the biggest drivers of Femara brand revenue decline versus generic letrozole?

Net price erosion and formulary substitution speed are the primary drivers.

4) Are there any non-generic IP barriers that block letrozole ANDAs?

Practically, most barriers are low due to off-patent status; residual formulation/process IP, if any, is narrow and defendant-specific.

5) What payer actions most influence Femara profitability?

PBM rebate structures and formulary placement that lock in lowest net cost generic labels.

---

References (APA)

1. FDA. (n.d.). Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
3. NCCN. (n.d.). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network.
4. ASCO. (n.d.). Clinical Practice Guidelines. American Society of Clinical Oncology.